Morepen LAB. Ltd
NSE: MOREPENLAB · Pharmaceuticals · sector
₹126.01NSE close 2026-10-26
Key numbers
Market cap₹6,904 cr
Price₹126.01
52w high / low₹151 / ₹33
P/E49.2xSector median 27.9x
P/B5.5xSector median 2.9x
Book value₹22.8
Dividend yield0.16%Sector median 0.48%
ROE11.7%Sector median 11.7%
ROCE13.6%Sector median 12.3%
OPM10.8%Sector median 14.0%
Debt / equity0.16xSector median 0.16x
EV/EBITDA33.4xSector median 18.6x
Interest cover11.4x
Current ratio2.37x
Sales growth 3y+8.4%Sector median +9.6%
Profit growth 3y+34.9%Sector median +13.3%
PEG1.59x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹92 cr vs borrowings ₹195 cr (FY26): borrowings are higher by ₹103 cr.
- Borrowings rose in each of the last 3 years (₹25 cr → ₹195 cr).
- Operating profit covered interest 11.4x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 5 of the last 5 years (FY26, FY25, FY24, FY23, FY22).
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 16% of net profit in the last 12 months.
- Dividend paid in 1 of the last 5 financial years.
- Price ₹126.01 on 2026-10-26: -16.4% from the 52-week high, +281.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹133.72 · low ₹35.33
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 |
| EBITDA | 44 | 36 | 42 | 24 | 57 | 46 | 24 | 83 |
| OPM % | 10.1% | 8.0% | 9.1% | 5.7% | 13.7% | 9.6% | 5.0% | 14.5% |
| Other income | 5 | 5 | 5 | 4 | 5 | 4 | 8 | 5 |
| Net profit | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 |
| EPS (₹) | 0.65 | 0.49 | 0.35 | 0.20 | 0.75 | 0.50 | 0.28 | 1.03 |
| Revenue YoY | -6.0% | +6.9% | +4.1% | +34.1% | ||||
| Profit YoY | +17.3% | +3.1% | -22.5% | +424.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 | 1,951 |
| EBITDA | 137 | 80 | 159 | 174 | 151 | 210 |
| Net profit | 102 | 39 | 96 | 118 | 95 | 141 |
| EPS (₹) | 2.26 | 0.77 | 1.88 | 2.20 | 1.73 | 2.56 |
| Revenue growth | -8.4% | +19.3% | +7.2% | -0.3% | +9.5% | |
| Profit growth | -62.0% | +148.6% | +22.7% | -19.6% | +51.8% | |
| Dividend / share (₹) | – | – | – | – | 0.20 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +8.4% | +8.7% | +9.5% |
| Net profit | +34.9% | -0.5% | +51.8% |
| EPS | +31.0% | -4.3% | – |
| Share price | – | +18.6% (2y) | +134.8% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 753 | 847 | 1,156 | 1,246 |
| Borrowings | – | 25 | 29 | 79 | 195 |
| Cash & equivalents | – | 56 | 52 | 127 | 92 |
| Total assets | – | 1,110 | 1,293 | 1,778 | 1,936 |
| Fixed assets | – | 167 | 213 | 317 | 381 |
| Capital work in progress | – | 17 | 24 | 28 | 22 |
| Investments | – | 0 | 1 | 7 | 101 |
| Receivables | – | 263 | 325 | 325 | 333 |
| Inventory | – | 229 | 249 | 300 | 272 |
| Payables | – | 227 | 295 | 363 | 317 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -58 | -91 | 73 | 32 | 33 |
| Cash from investing | -32 | -47 | -83 | -322 | -123 |
| Cash from financing | 64 | 144 | 5 | 300 | 97 |
| Capex | 67 | 46 | 81 | 214 | 161 |
| Free cash flow | -125 | -137 | -8 | -182 | -128 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 5.1% | 11.3% | 10.2% | 7.6% |
| ROCE % | – | 7.4% | 15.9% | 13.2% | 9.5% |
| Debtor days | – | 68 | 70 | 65 | 67 |
| Inventory days | – | 87 | 85 | 94 | 88 |
| Payable days | – | 87 | 101 | 114 | 103 |
| Cash conversion cycle (days) | – | 68 | 54 | 45 | 52 |
| Working capital days | – | 112 | 105 | 133 | 136 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 35.65% |
| FIIs | 3.43% |
| DIIs | 1.71% |
| of which Mutual funds | 0.00% |
| of which Insurance | 0.81% |
| Government | 0.01% |
| Public (non-institutions) | 59.19% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% | 35.65% |
| Promoter group | % |
|---|---|
| Scope Credits and Financial Services PVT. Ltd. | 2.84% |
| Concept Credits and Consultants PVT. Ltd. | 2.80% |
| Brook Investments and Financial Services PVT. Ltd | 2.77% |
| Solitary Investments and Financial Services PVT. Ltd. | 2.76% |
| Solace Investments and Financial Services PVT. Ltd. | 2.75% |
| MID MED Financial Services and Investments PVT. Ltd. | 2.73% |
| React Investments and Financial Services PVT. Ltd. | 2.73% |
| Epitome Holdings PVT.LTD. | 2.65% |
| Seed Securities and Services PVT. Ltd. | 2.61% |
| Square Investments and Financial Services PVT. Ltd. | 2.57% |
| Sushil Suri | 1.00% |
| Anju Suri | 0.95% |
| Liquid Holdings PVT. Ltd. | 0.91% |
| Sonia Pankaj Bajaj | 0.67% |
| Sanjay Suri | 0.62% |
| Public holders above 1% | % |
|---|---|
| Pinfold Overseas Limited | 6.39% |
| Morepen Laboratories Limited | 1.02% |
4,03,932 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| MOREPENLAB | ₹6,904 cr | 49.2x | 5.5x | 11.7% | 13.6% | 10.8% | +8.4% | 0.16% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-18 | Dividend | Dividend - Re 0.20 Per Share |
| 2025-08-29 | Dividend | Dividend - Re 0.20 Per Share |
| 2024-09-20 | Other | Annual General Meeting |
| 2023-09-21 | Other | Annual General Meeting |
| 2022-09-19 | Other | Annual General Meeting |
| 2021-09-20 | Other | Annual General Meeting |
| 2020-09-22 | Other | Annual General Meeting |
| 2019-09-05 | Other | Annual General Meeting |
| 2018-09-12 | Other | Annual General Meeting |
| 2017-09-14 | Other | Annual General Meeting |
| 2016-09-15 | Other | Annual General Meeting |
| 2015-09-10 | Other | Annual General Meeting |
| 2014-09-11 | Other | Annual General Meeting |
| 2014-08-08 | Other | E - Voting |
| 2013-09-05 | Other | Annual General Meeting |
| 2012-09-07 | Other | Annual General Meeting |
| 2011-09-09 | Other | Annual General Meeting |
| 2009-09-11 | Other | Annual General Meeting |
| 2008-06-27 | Other | Annual General Meeting |
| 2007-08-17 | Other | Agm |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- API Business: Products like Loratadine, Montelukast, Atorvastatin etc
- Medical Devices Business: BP Monitors, Glucometers etc
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | MOREPENLAB |
| BSE code | 500288 |
| ISIN | INE083A01026 |
| Face value | ₹2.0 |
| Incorporated | 1984-12-01 |
| Website | www.morepen.com |
| Plants (India / abroad) | 4 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.